Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β-Lactamase Inhibitors.

Ahmed M Soliman, Heba Abdelrasheed Allam, Walaa R Mahmoud, Bassem H Naguib

Abstract read

In one paragraph

Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmed M SolimanPharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Shorouk, Egypt.ORCID https://orcid.org/0009-0004-3177-3177

Heba Abdelrasheed AllamPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0000-0001-6176-7035

Walaa R MahmoudPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID https://orcid.org/0000-0002-1451-9159

Bassem H NaguibPharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Shorouk, Egypt.ORCID https://orcid.org/0009-0009-7175-2078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of new substituted 1,6-dihydropyrimidinones was designed, synthesized, and biologically evaluated as potential antibacterial candidates and β-lactamase enzyme inhibitors. All the synthesized compounds were tested for their antibacterial activity against Staphylococcus aureus, Bacillus subtilis as a gram-positive species whereas Pseudomonas aeruginosa as a gram-negative species was utilized. Most of the compounds exhibited moderate antibacterial activity compared to the reference drug amoxicillin. Furthermore, clinical antibacterial tests were conducted on β-lactamase resistant strains, including Acinetobacter baumannii, Bacillus subtilis, and Staphylococcus aureus. Results indicated that the candidate compounds possess potentiation effect, indicating their role as effective β-lactamase enzyme inhibitors. Whereas in-vitro assay performed on β-lactamase enzymes revealed that compounds 3d, 3i, and 7b (IC

Indexed as

Anti-Bacterial Agentsbeta-Lactamase InhibitorsDrug DesignPyrimidinonesAcinetobacter baumanniiBacillus subtilisbeta-LactamasesMicrobial Sensitivity TestsPseudomonas aeruginosaStaphylococcus aureusStructure-Activity RelationshipAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesPyrimidinonesantimicrobial assaydihydropyrimidinonesβ‐lactamase inhibitor antibacterial agents

Identifiers

PMID42552741

DOI10.1111/cbdd.70374

PMCPMC13438106

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.